A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Inclusion Criteria: * Adults with confirmed CKD; UACR ≥30 mg/g and eGFR ≥20 mL/min/1.73 m² within specified ranges. * On stable, patient maximum tolerated, labeled daily dose of ACEI or ARB for ≥4 weeks at least 28 days before screening. Exclusion Criteria: * BMI \<23 kg/m² at screening * History of type 1 diabetes mellitus * HbA1c ≥10% (86 mmol/mol) at screening * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema. * Have had more than one episode of severe hypoglycemia within 180 days prior to screening, or hypoglycemia unawareness * Acute coronary syndrome, major cardiac procedure, stroke, or TIA within 3 months prior to screening * Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * History/family history (first degree) of medullary thyroid cancer or MEN2